GlassScriptPhysician profile
Cierra N Williams
NPI 1730557752
$1,528.01
in general payments reported to CMS, 2019-2025
17 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $333 · 2023: $166 · 2024: $267 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922 · Education: $97.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.42 |
| Education | $97.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $320.04 | 2021-2025 | Krystexxa, Aranesp |
| Horizon Therapeutics Plc | $269.99 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $223.15 | 2021-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $95.13 | 2021-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $88.75 | 2025 | |
| Vifor Pharma, INC. | $78.21 | 2021-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $74.07 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $60.75 | 2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $56.02 | 2025 | |
| Travere Therapeutics, INC. | $55.99 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $55.98 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $39.29 | 2022-2024 | Auryxia |
| Ardelyx, INC. | $26.84 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.53 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $21.46 | 2023 | Sunosi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $20.46 | 2021 | |
| Novo Nordisk INC | $16.35 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cierra Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.